5 Results for "

bone marrow mononuclear cells

" in MedChemExpress (MCE) Product Catalog:
Products (5)

5 Results for "bone marrow mononuclear cells" in MCE Product Catalog:

Cat. No.: HY-160696
CAS No.: 2641306-62-7
Target:  

CD73

Research Areas:  

Cancer

ORIC-533 is an orally active, highly selective, AMP-competitive CD73 inhibitor that potently blocks adenosine production with sub-nanomolar affinity (Ka=0.03 nM). In multiple myeloma, ORIC-533 restores and enhances the cytotoxicity of the immune system against tumor cells through multiple immunological mechanisms, including reversing the immunosuppressive microenvironment, inducing immunogenic cell death, and activating dendritic cells, T cells and NK cells, with no direct toxicity to normal cells. The combination of ORIC-533 with Daratumumab (HY-P9915) synergistically enhances anti-tumor efficacy, significantly increases intratumoral CD8 + T cell infiltration and inhibits tumor growth in vivo .
loading...
    loading...
Cat. No.: HY-106850
CAS No.: 84472-85-5
Purity:  99.11%
Synonyms: AzdU; AzddU; CS-87
Target:  

HIV

Research Areas:  

Infection

3′-Azido-2′,3′-dideoxyuridine (AzdU) is a nucleoside analog of Zidovudine (HY-17413). 3′-Azido-2′,3′-dideoxyuridine is a potent inhibitor of human immunodeficiency virus (HIV) replication in human peripheral blood mononuclear cells (PBMC) with limited toxicity for human bone marrow cells (BMC) . 3′-Azido-2′,3′-dideoxyuridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
loading...
    loading...
Cat. No.: HY-P992058
Synonyms: ART-140; DNP-001; EGX-040
Research Areas:  

Cancer

Leukotuximab (ART-140; EGX-040) is an anti-JL1 mAb and an anti-leukemic agent. Leukotuximab targets the JL1 epitope of CD43 and exerts cytotoxic effects on JL1-positive leukemia cells. Except for thymocytes and some bone marrow mononuclear cells, Leukotuximab causes no damage to most normal tissues. Leukotuximab can be used in the research of acute myeloid leukemia, acute lymphoblastic leukemia, and myelodysplastic syndrome .
loading...
    loading...
Cat. No.: HY-183965
Research Areas:  

Cancer

PLK3-IN-1 is a selective Polo-like kinase 3 (PLK3) inhibitor with a human PLK3 IC50 of 5 nM. PLK3-IN-1 can be used for cancer research .
loading...
    loading...
Cat. No.: HY-K3036

MCE IMDM (Iscove's Modified Dulbecco's Medium) is an enriched formulation modified from DMEM, containing high concentrations of glucose, sodium pyruvate, amino acids, vitamins, HEPES buffer, selenium, and other essential nutrients. It is designed to meet the nutritional requirements for rapid cell proliferation and high-density culture, supporting a variety of cell types, including Jurkat cells, COS-7 cells, and macrophages. The product specifications are based on the 500 mL format, and larger volume packages are provided as multiples of this standard specification.

loading...
    loading...